Because of their favorable efficacy and safety profile, DPP-4 inhibitors may be a therapeutic option for many patients with type 2 diabetes, especially older adults, patients with renal or hepatic impairments, and patients at risk for hypoglycemia. DPP-4 inhibitors carry a low incidence of adverse events such as hypoglycemia and gastrointestinal side effects and are considered weight neutral. In addition, studies have suggested that DPP-4 inhibitors may reduce albuminuria and improve various renal inflammatory markers.
Although DPP-4 inhibitors may be safe to use in patients with heart failure, they have not been shown to reduce adverse cardiovascular outcomes.
Learn more about DPP-4 inhibitors use in type 2 diabetes.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori, Anne L. Peters. Fast Five Quiz: Type 2 Diabetes Incretin-Based Therapy - Medscape - Apr 28, 2023.